6.585

0.69% 0.045

Wave Life Sciences Ltd (WVE)

Overview News Price History Option Chain Financials Why WVE Down? Discussions Forecast

Wave Life Sciences Ltd stock is traded at $6.585, with a volume of 1.55M. It is up +0.69% in the last 24 hours and up +7.25% over the past month. WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Previous Close:

$6.54

Open:

$6.53

24h Volume:

1.55M

Relative Volume:

1.12

Market Cap:

$1.25B

Revenue:

$53.61M

Net Income/Loss:

$-142.52M

P/E Ratio:

-5.9324

EPS:

-1.11

Net Cash Flow:

$-141.83M

1W Performance:

-18.70%

1M Performance:

+7.25%

6M Performance:

-59.95%

1Y Performance:

+14.32%

1-Day Range:

$6.40

$6.705

1-Week Range:

$5.62

$8.23

52-Week Range:

$4.25

$16.73

Wave Life Sciences Ltd Stock (WVE) Company Profile

Name

Wave Life Sciences Ltd

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

617-949-2900

Address

7 STRAITS VIEW, SINGAPORE

Employee

288

Twitter

@WAVELifeSci

Next Earnings Date

2025-03-04

Latest SEC Filings

WVE's Discussions on Twitter

Compare WVE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
WVE Wave Life Sciences Ltd	6.585	1.25B	53.61M	-142.52M	-141.83M	-1.11
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight
Apr-08-25	Initiated	Wedbush	Outperform
Feb-25-25	Initiated	Jefferies	Buy
Oct-16-24	Upgrade	Raymond James	Outperform → Strong Buy
Sep-27-24	Resumed	JP Morgan	Overweight
Sep-19-24	Initiated	B. Riley Securities	Buy
Sep-09-24	Initiated	JP Morgan	Overweight
May-15-24	Initiated	Wells Fargo	Overweight
Dec-19-23	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-05-23	Initiated	Raymond James	Outperform
May-24-23	Downgrade	Jefferies	Buy → Hold
Dec-15-20	Resumed	H.C. Wainwright	Buy
Oct-23-20	Initiated	RBC Capital Mkts	Sector Perform
Dec-31-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Nov-01-19	Initiated	Guggenheim	Buy
Jul-15-19	Initiated	Cowen	Market Perform
Apr-17-19	Reiterated	H.C. Wainwright	Buy
Aug-07-18	Initiated	Stifel	Buy
Jul-23-18	Initiated	H.C. Wainwright	Buy
Mar-19-18	Reiterated	Mizuho	Buy
Feb-15-17	Initiated	H.C. Wainwright	Buy
Nov-10-16	Resumed	Leerink Partners	Outperform
Dec-07-15	Initiated	JMP Securities	Mkt Outperform
Dec-07-15	Initiated	Jefferies	Buy
Dec-07-15	Initiated	Leerink Partners	Outperform
Dec-07-15	Initiated	Sun Trust Rbsn Humphrey	Buy

View All

Wave Life Sciences Ltd Stock (WVE) Latest News

May 09, 2025

Despite shrinking by US$215m in the past week, Wave Life Sciences (NASDAQ:WVE) shareholders are still up 407% over 3 years - simplywall.st

May 09, 2025

RBC Cuts Price Target on Wave Life Sciences to $9 From $10, Keeps Sector Perform, Speculative Risk - marketscreener.com

May 09, 2025

Wave Life Sciences Reports Q1 2025 Financials and Progress - TipRanks

May 09, 2025

Wave Life Sciences: Q1 Earnings Snapshot - New Haven Register

May 09, 2025